JP2017526747A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526747A5
JP2017526747A5 JP2017530956A JP2017530956A JP2017526747A5 JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5 JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5
Authority
JP
Japan
Prior art keywords
manufacturing process
process according
crystallized particles
mixture
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530956A
Other languages
English (en)
Japanese (ja)
Other versions
JP6591546B2 (ja
JP2017526747A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/046525 external-priority patent/WO2016032950A1/en
Publication of JP2017526747A publication Critical patent/JP2017526747A/ja
Publication of JP2017526747A5 publication Critical patent/JP2017526747A5/ja
Application granted granted Critical
Publication of JP6591546B2 publication Critical patent/JP6591546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530956A 2014-08-25 2015-08-24 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス Active JP6591546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
US62/041,341 2014-08-25
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019169473A Division JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Publications (3)

Publication Number Publication Date
JP2017526747A JP2017526747A (ja) 2017-09-14
JP2017526747A5 true JP2017526747A5 (enExample) 2019-09-12
JP6591546B2 JP6591546B2 (ja) 2019-10-16

Family

ID=55347322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530956A Active JP6591546B2 (ja) 2014-08-25 2015-08-24 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
JP2019169473A Pending JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019169473A Pending JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Country Status (20)

Country Link
US (5) US10064859B2 (enExample)
EP (2) EP3185867B1 (enExample)
JP (2) JP6591546B2 (enExample)
CN (2) CN111454207B (enExample)
AU (2) AU2015306910B2 (enExample)
CA (1) CA2959329C (enExample)
CY (1) CY1124058T1 (enExample)
DK (1) DK3185867T3 (enExample)
ES (2) ES2862098T3 (enExample)
HR (1) HRP20210551T1 (enExample)
HU (1) HUE054641T2 (enExample)
IL (1) IL250661B (enExample)
LT (1) LT3185867T (enExample)
MA (2) MA40480B1 (enExample)
PL (1) PL3185867T3 (enExample)
PT (1) PT3185867T (enExample)
RS (1) RS61709B1 (enExample)
SI (1) SI3185867T1 (enExample)
SM (1) SMT202100212T1 (enExample)
WO (1) WO2016032950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
ES2862098T3 (es) * 2014-08-25 2021-10-07 Alkermes Pharma Ireland Ltd Proceso de cristalización de derivados de aripiprazol en formulaciones de liberación prolongada para el tratamiento de la esquizofrenia
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
ES2903278T3 (es) 2017-07-28 2022-03-31 Interquim Sa Procedimiento para la preparación de aripiprazol lauroxil
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
PT1675573E (pt) * 2003-10-23 2008-12-30 Otsuka Pharma Co Ltd Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
AU2008340101C1 (en) 2007-12-19 2025-03-06 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
EP2661246A4 (en) * 2011-01-07 2015-07-29 Neodyne Biosciences Inc Wound or skin treatment devices and methods
HRP20240285T1 (hr) * 2011-03-18 2024-05-24 Alkermes Pharma Ireland Limited Farmaceutski pripravci koji sadrže sorbitan estere
AU2013235519C1 (en) * 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
ES2792149T3 (es) * 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
ES2862098T3 (es) * 2014-08-25 2021-10-07 Alkermes Pharma Ireland Ltd Proceso de cristalización de derivados de aripiprazol en formulaciones de liberación prolongada para el tratamiento de la esquizofrenia

Similar Documents

Publication Publication Date Title
JP2017526747A5 (enExample)
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
JP2015081383A (ja) 銀ナノワイヤの調製方法
JP2017505347A5 (enExample)
JP2016000763A5 (enExample)
HRP20160886T1 (hr) Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva
JP2018528948A5 (enExample)
ES2647239T3 (es) Proceso para producir cristales de ácido polimórfico 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico mediante método de adición de solvente pobre
JP2017160107A5 (enExample)
JP2016515517A5 (enExample)
JP2016074548A5 (enExample)
JP2019529553A5 (enExample)
CN106083963A (zh) 一种索非布韦晶型6的制备方法
JP2007530652A5 (enExample)
CN114746399B (zh) 羧甲司坦的制备方法
JP2014506577A5 (enExample)
JP2020500907A5 (enExample)
CN104739789B (zh) 含有索利那新或其盐的药物组合物
CN103820856B (zh) Lbo晶体生长原料的合成方法及制备lbo晶体的方法
WO2016104960A3 (ko) 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법
CN106435835A (zh) 一种用于高温炉辊耐火纤维的制备方法
CN104193747B (zh) 替卡格雷无定形的制备
JP2016520122A5 (enExample)
JP2020502280A5 (enExample)
CN102139917A (zh) 一种介孔二氧化钛材料的制备方法